• Canada’s first nationally legal cannabis-infused edible products began hitting store shelves December 17, vastly broadening the market for products using the plant’s extracts
• Lexaria Bioscience has dedicated years of research to the development of its proprietary DehydraTECH technology, designed to enhance the effectiveness of orally consumed drug products such as cannabis as well as nicotine
• Testing of Lexaria’s 2.0 version of its DehydraTECH technology shows enormous improvement in the speed of payload delivery to the bloodstream, as well as the potential for delivering drugs across the body’s largely impenetrable blood-brain barrier to the central nervous system

Canada’s regulatory innovations in making cannabis products accessible nationwide for both therapeutic and recreational purposes have led to this year’s ‘Cannabis 2.0’ national rollout of laws for a new edible cannabis-infused market. Cannabis edibles, extracts and topicals became legal in October pending a 60-90-day regulatory approval process for product applications, and that timeline resulted in the first legal edibles becoming available December 16 (http://ibn.fm/qFZdX), just in time for Christmas, subject to retailers’ delivery schedules.

Oral drug product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is well situated to take advantage of the market arising from Canada’s sweeping legal changes, as well as the burgeoning market for infused edibles in select states within the United States. Lexaria’s own ‘2.0’ version of its patented DehydraTECH™ oral drug delivery technology has shown an ability in lab animal testing to deliver 811 percent more cannabidiol (CBD) into the bloodstream than generic industry control formulations, nearly doubling the capacity of existing DehydraTECH technology, a news release states (http://ibn.fm/Utl7A).

The company’s 2.0 technology is specifically being developed for effectiveness in helping to deliver its drug payload across the blood-brain barrier, a natural biological system of blood vessels and endothelial cells that bar most drugs from accessing the brain’s central nervous system hierarchy. The ability to effectively deliver drugs to the brain is of keen interest to developers of drugs designed to beneficially target the central nervous system.

Lexaria’s research and development showed that DehydraTECH version 2.0 was able to deliver 1,937 percent more CBD into brain tissue than generic industry control formulations and 487 percent more than the original DehydraTECH technology, according to the company’s news release.

Deloitte market analysts estimate that the total cannabis market in Canada alone, where the market allows for federal scale, will produce up to $7.17 billion in sales this year, the vast majority from approved recreational-use products. While edibles currently make up a small portion of the overall cannabis market, Deloitte found that six out of 10 likely cannabis consumers will choose to use edible products, particularly when it comes to baked goods (http://ibn.fm/gVhe7).

Deloitte researchers predict the Canadian market for edibles and alternative cannabis products will be worth $2.7 billion a year, with extract-based products making up nearly 60 percent of the total (http://ibn.fm/iu82y).

Lexaria also recently announced pilot lab trials in humans that showed the recreational tetrahydrocannabinol (THC) cannabinoid demonstrated effectiveness in less than 10 minutes with version 2.0 – about twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations for oral consumption (http://ibn.fm/lWR1X).

While cannabis’ popularity has been an explosive new market force, the DehydraTECH technology isn’t dedicated to it exclusively. DehydraTECH has been in development as a solution to health problems associated with smoked or vaped drug delivery over the course of the past three years, including alternatives to tobacco’s nicotine cigarette inhalation. DehydraTECH’s developmental goal is to provide an oral drug consumption method that provides effectiveness as rapidly as inhaled substances, thereby eliminating any practical reason for smoking or vaping and their potential harm to users’ throats and lungs.

Lexaria has licensed its technology to multiple companies in the cannabis and tobacco industries. The company operates a licensed in-house research laboratory and its IP portfolio includes 16 patents granted and over 60 patents pending worldwide. The company received a cannabis research and development license from Health Canada in August (http://ibn.fm/mRaIh), and recently announced the closing of private placement fund-raising for gross proceeds of about $820,000 (http://ibn.fm/WFDoK) with additional warrant opportunities.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• ‘Streaming wars’ generate growing demand for fresh content, with leading streaming service providers spending billions on content annually
• Wonderfilm already has a film library with 250 titles and is producing new original content on a regular basis to meet rising demand
• Company expects to generate $100 million in revenue by 2021, $20 million in deferred revenue early next year
• Approximately 69% of U.S. households now subscribe to streaming video services, up from 55% in 2017

Streaming is a highly lucrative segment fueled by the demand to control one’s own entertainment, which gave rise to the VCR back in the 1970s. The media has dubbed this pronounced entertainment conflict the ‘streaming wars’. The race to capture content streaming consumers is a key feature of modern-day entertainment, as shown during a broadcast (http://ibn.fm/0diUt) titled ‘Filmmakers Poised for Big Gains in Hollywood’s Streaming Wars’.

In this race, providers of streaming video on demand are making major investments to secure existing content and commission new content. Efforts are being made to attract major producers and filmmakers. This demand has given companies such as Wonderfilm Media Corporation (TSX.V: WNDR) (OTCQB: WDRFF), a leading entertainment organization producing internationally appealing, high-quality feature films and episodic television, a prime opportunity to claim a piece of the pie.

Wonderfilm has around 100 films of its 250-title library already streaming on the Netflix platform. The company has a unique business model where it differentiates itself by setting up each film as a single-purpose entity packaged for upfront sale, thereby eliminating filmmaking risk (http://ibn.fm/Minb2). In addition, Wonderfilm typically produces low-risk, easy-to-sell films featuring a desirable cast and genre that all but guarantee the financial success of each production.

A Wonderfilm movie is pre-sold for roughly $5 million, which incurs a 10 percent commission to distribution companies. Since the company distributes its films via Wonderfilm Global, a film, television and media foreign sales/distribution joint venture where Wonderfilm Media Corporation has 51 percent ownership, this 10 percent commission remains in-house instead of going to third parties.

Additionally, Wonderfilm makes money from producing fees that are added to the production budget and from overages above the presale threshold. Wonderfilm owns the films after their sale terms end. The company also profits from unsold presale territories, which are countries or territories left off of a film’s presale list.

Wonderfilm retains a continuing annual production slate of $58 million to meet the constant and growing need for content worldwide and has eight green-lit features representing $60 million U.S. in production budgets currently in development (http://ibn.fm/DEBwa). The company expects $20 million in deferred revenue in early 2020 alone and is positioned to realize $100 million in revenue by 2021.

Some of Wonderfilm’s most notable upcoming releases are the action film Inside Game, starring Tyrese Gibson, slated for a fall 2020 theatrical release, as well as the horror film Amityville 1974, which will hit theaters in October 2020. Other IP projects developed by Wonderfilm include a Steve McQueen biopic, a TV series helmed by CSI: Crime Scene Investigation creator Anthony Zuiker and a screen adaptation of renowned novel Merchant of Death.

Deloitte analysts report that for the first time in history, a higher percentage of U.S. households subscribed to a digital streaming service than to traditional pay television. 69% of U.S. households now subscribe to streaming video services, up from 55% in 2017 (http://ibn.fm/6CjLB), and PwC research indicates that consumers are willing to spend more to get the content they want, with total global spending on entertainment and media expected to grow at a CAGR of 4.4% over the next five years to reach $2.4 trillion in global revenue by 2022 (http://ibn.fm/ZBrGa). This provides an excellent opportunity for Wonderfilm, which is already leveraging its rich production schedule and unique business model to profit from the rising demand for streaming content.

For more information, visit the company’s website at www.Wonderfilm.com

NOTE TO INVESTORS: The latest news and updates relating to WDRFF are available in the company’s newsroom at http://ibn.fm/WDRFF

• CEO says record sales prove SHRG’s “sales and support strategies are on the right path”
• Company projects investment of estimated $200,000 in second half of FY2020 for information technology systems upgrade
• SHRG’s consolidated gross profit grew by $16.2 million to $27.4 million for three months ended October 31, 2019, compared to same period prior year

Sharing Services Global Corporation (OTCQB: SHRG) in its 10-Q filed with the SEC for the three months ended October 31, 2019, reported sales of $38,850,483 for Q2 2019, or 116% greater than the $17,973,379 SHRG reported for the comparable quarter last year (http://ibn.fm/osL5U). Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

In the filing, SHRG further reported that its consolidated operating earnings were $3.9 million in the fiscal quarter ended October 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended October 31, 2019, compared to 62.2% the prior year (http://ibn.fm/e4E09). The company said the higher margins partly resulted from the economies of scale achieved by shipping more product.

The filing continued to describe SHRG’s intention to implement a system to upgrade its information technology system in the second half of fiscal year 2020; the approximate cost for the upgrade will be $200,000. This announcement comes on the heels of a comprehensive assessment of the system in the six-month period ending October 31, 2019.

Sharing Services’ Q2 record revenues continues the trend of Q1 2019, the three months ending July 31, when SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018 (http://ibn.fm/y5ANF). These numbers bring SHRG’s sales revenues since December 2017 to an impressive cumulative total of $169 million. One significant contributor to the company’s success seems to be its December 2017 launch of a proprietary line of products through its Elepreneurs and Elevacity subsidiaries.

“Product sales for our incredible health and wellness products of Elevacity Global continue to be strong, consistently increasing each quarter,” SHRG CEO John “JT” Thatch stated in a news release. “Our Q2 revenues demonstrate that our sales and support strategies are on the right path as we continue to grow in the direct-selling marketplace.” Thatch credited SHRG’s independent distributors, called Elepreneurs, and its corporate office team for the company’s gains.

SHRG’s Elepreneurs are seeing remarkable success as they employ the company’s Blue Ocean selling strategy in the direct-sales market (http://ibn.fm/JbMYg). The Blue Ocean Strategy is an approach to selling that makes competition irrelevant by creating and operating in an uncontested market space.

The launch of SHRG’s proprietary line of health and wellness products in 2017, through its Elepreneurs and Elevacity subsidiaries, was a milestone for the company. The product line consists of three sectors: anti-aging skin care, functional beverages and natural supplements. All are based on the company’s exclusive D.O.S.E. product formulation of four hormones designed to promote happiness and well-being (http://ibn.fm/fALYi). Thatch said the company would continue to evaluate its expansion plans, products, and strategies as it endeavors to continue its success in 2020.

Sharing Services Global Corporation is a diversified company, with Elepreneurs Holdings and Elevacity Holdings being its primary operating subsidiaries. SHRG markets and distributes health and wellness products that are sold under the Elevate brand through an independent sales force of distributors, or Elepreneurs, using the direct-selling business model. Sharing Service’s current product offerings include its Elevate health and wellness product line, launched in December 2017. The company’s Elevate product line consists of nutraceutical products referred to as D.O.S.E., which refers to key hormones dopamine, oxytocin, serotonin, and endorphins.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at  http://ibn.fm/SHRG

• Increased pollution, rising population and climate change all straining worldwide water supply
• Biggest issue that keeps U.S., other countries from success is reliance on centralized water technologies
• Infrastructure failure can be addressed by developing decentralized, onsite and modular water-treatment systems like OriginClear Inc.’s innovative products

Recycling water is a worldwide issue, according to OriginClear Inc. (OTC: OCLN) CEO Riggs Eckelberry, who noted that with issues such as increased pollution, rising population and climate change all straining worldwide water supply, poor levels of water recycling are not sustainable.

“Leaders across all industries need to rethink their entire approach to using and delivering water,” Eckelberry noted in a recent article (http://ibn.fm/0BXVG) titled ‘Israel Recycles 90 Percent of Its Water, the U.S. Recycles 1 Percent. Here’s How We Can Change That’.

In the article, Eckelberry described the varying levels of water advancement found in countries around the globe. He referenced the lack of consistency in countries industrial advancements, especially regarding water technology. Achieving a level of 90% water recycling, Israel is the world leader by far; Spain ranks second at only 20%. Alarmingly, America lags behind at a mere 1%.

OriginClear is on a mission to change those numbers, seeing tremendous potential in the future of water management around the world.

“The biggest issue that keeps the United States and other areas of the world from reaching Israel’s exceptional level of success is the reliance on centralized water technologies,” Eckelberry said. “An estimated 90% of people in the United States rely on mega-facilities for water treatment and distribution, both for home and business use. That means that, to a large degree, people have very little control over their water.”

Complicating the matter is the fact that those facilities are breaking down, Eckelberry explained. Unfortunately, “maintaining and repairing them balloons the already unnecessarily high price tag of moving water from one place to another safely. And increasingly, it’s just not economically viable to keep the facilities open at all.”

The good news is that the infrastructure failure can be addressed by developing and using decentralized, onsite and modular water-treatment systems, said Eckelberry. “These systems can scale based on personal, business or community needs. They also can be built flexibly in ways that address specific geographical concerns or advantages.”

OriginClear is leading the way to water decentralization. A leading provider of these types of water-treatment solutions, OriginClear offers breakthrough water-treatment and conveyance products that can effectively improve the quality of water around the world by returning it to its original and clear condition. The company’s stated mission is to empower this global movement with modular water-treatment and conveyance products that enable water independence and help make clean water available globally.

For more information, visit the company’s website at www.OriginClear.com

NOTE TO INVESTORS: The latest news and updates relating to OCLN are available in the company’s newsroom at http://ibn.fm/OCLN

• ChineseInvestors.com has become top financial-information website
• The company is also advancing its cannabidiol program
• CIIX offers investors multiple revenue streams, healthy return potential

Based in San Gabriel, California, ChineseInvestors.com Inc. (OTCQB: CIIX) offers a proprietary financial-news media and content platform. The company has become a foremost financial-information website for Chinese-speaking investors in the United States and China. Via its main website – www.ChineseInvestors.com – CIIX offers an array of investor-education products and services. CIIX is also laying the foundation to capitalize on increasing demand for CBD (cannabidiol)-based nutrition and health products.

CIIX’s investor-education products and services include real-time market commentary, analysis and educational-related services in Chinese-language character sets. The company also provides consultative services to smaller private companies considering becoming public, as well as advertising and public-relations-related support services.

As a core element of its services, CIIX features its exclusive ChineseInvestors Method, an innovative integration of a disciplined investing process, web-based tools, personalized instructions and invaluable support. With this strategy, the company provides reliable market information to assist investors in making informed investment decisions and meeting their individual financial goals.

CIIX raises investor awareness through investor conferences and road shows. The company has a subscriber base of free and paying members, with its base membership – 95% – primarily located in the United States and Canada. CIIX services are largely delivered to U.S. public and private companies and U.S. residents and citizens. The company delivers its services in both traditional and simplified Chinese-language character sets (http://ibn.fm/wFVFL).

CIIX’s CBD initiatives are carried out by its subsidiary, CBD Biotech Inc. In essence, CIIX is taking advantage of its own financial expertise to establish itself as a leader in China’s developing CBD industry. Through CBD Biotech, CIIX has established a three-year development plan to capitalize on the union of CBD and the nutrition and health products market in mainland China.

Subsequent to entering into a wholesale agreement with a well-known CBD health brand in December 2016, CIIX formally launched the website ChineseCBDOil.com (http://ibn.fm/dtgJL). This website is one of the world’s first online stores in the Chinese language, providing industrial-hemp-derived CBD products for Chinese-speaking customers around the world. Products available on the site include soft gels, capsules and concentrates. In addition, CIIX opened a retail store in San Gabriel, California, which has a high Chinese population.

Of note to investors is that CIIX CEO Warren Wang has said the company is planning an IPO of wholly owned CBD Biotech. In the announcement, Wang noted that CIIX hopes for a Nasdaq IPO of CBD Biotech early in 2020. CIIX would then concentrate on identifying an acquisition target for further growth (http://ibn.fm/I1iRR).

CIIX continues to focus on providing premier financial information via its main website. At the same time, the company is leveraging the opportunity for significant revenue streams through its CBD Biotech subsidiary. For investors, CIIX offers a two-pronged business strategy for a healthy return on investment.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• 3D-printed weight-optimized and flow-optimized parts significantly improve the performance of aircraft and rockets
• Global aerospace 3D-printing market estimated at $1.4 billion in 2018, projected to reach $6.8 billion by 2026
• Sigma Labs’ breakthrough quality-assurance solution PrintRite3D® set to revolutionize 3D-printing industry, enabling it to grow globally

Sigma Labs Inc. (NASDAQ: SGLB) is set to exploit the tremendous aerospace 3D-printing-market growth potential with its revolutionary in-process, quality-assurance technology. This technology is poised to help the industry scale a critical hurdle: ensuring effective and efficient quality in real time.

The global aerospace 3D-printing market was estimated at $1.4 billion in 2018, projected to reach $6.8 billion by 2026 with an expected CAGR in excess of 22% during the forecast period. The airline and spacecraft segment is expected to lead the aerospace 3D-printing market due to the need for low-volume, low-weight parts that can be manufactured using 3D-printing technologies, which reduces supply chain constraints, minimizes warehouse space and lowers waste materials compared to traditional manufacturing processes (http://ibn.fm/cWh1C).

As the industry is challenged by environmental restrictions, high manufacturing cost and a competitive market environment, 3D metal components manufacturing offers a unique solution to help overcome much of these challenges.

Weight is considered the most important feature in the design and development of an aircraft because of its tremendous impact on fuel consumption. 3D-printing technology can help build lighter fuel-saving aircraft parts, a characteristic essential in an industry that operates at low-profit margins. Additive manufacturing provides advanced manufacturing techniques for developing the components, parts while maintaining the strength and aerodynamic features of an aircraft. This is an important motivating factor for airlines to procure newer generation aircraft, which will drive the growth of the additive-manufacturing sector. The aircraft segment currently holds the major share in 3D printing for the aerospace and defense market.

3D-printing technology also provides companies with a critical competitive advantage as it offers the flexibility to design and test products multiple times and quickly build prototypes, helping companies to cost effectively reduce uncertainties and improve the functionality of their products, thereby accelerating design cycles and reducing time to market.

By making the production process of components faster, cheaper, and simpler, while also enabling the seamless integration of components into a single structure and reducing the need for external joints, fasteners and adhesives, additive manufacturing has attracted interest from major aircraft manufacturers such as Boeing and Airbus B.V. as well as component producers such as Rolls-Royce, Pratt & Whitney and GE Aviation.

However, 3D-printing technology is facing a significant technical hurdle: real-time process monitoring and control. Due to variability in the 3D-printing process, consistent quality of produced parts is not reliably achieved without postproduction inspection, which is time consuming, costly and results in high rejection costs. Since components and parts can currently be inspected only by CT scans and other means, the producer doesn’t know until the end of the process if the finished parts meet design specifications, resulting in lost time and profits as well as the inability to economically scale up production.

Sigma Labs is revolutionizing the traditional quality assurance process with its quality-assurance software that operates in real-time, in process as parts are being formed unlike any other quality-assurance software on the market, Sigma Labs’ PrintRite3D® is a unique third-party validated software that enables real-time monitoring, analysis, feedback and control during the 3D-printing process of precision metal parts. PrintRite3D detects defects during the production process while providing feedback to machine operators allowing corrective actions to be taken , leading to faster production of metal parts with fewer errors and a more uniform product. Users will realize results in decreased downtime and waste while increasing yield and profits for 3D-printing companies.

Compared to its competitors, Sigma Labs’ PrintRite3D provides users with a superior solution. Most other solutions do not offer features such as crucial calibration filters, raw data export, machine-learning-enabled automated anomaly detection, and 3D thermal data visualization. Within the rapidly growing aerospace sector, Sigma Labs has been recognized as a superior solution to the industry’s critical needs and, as such, was selected by the industry-leading producer Airbus earlier this year to deploy its PrintRite3D Rapid Test and Evaluation Program.

With tier-1 clients such as Airbus, Siemens, Pratt & Whitney and Honeywell evaluating the software, Sigma Labs is on a clear path to break-even operations in 2020. The company is uniquely positioned to capture a significant part of the sizable addressable market with its proprietary technology that enables the entire 3D-metal-printing industry to overcome the single most-significant barrier to adoption in serial production.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• SING announces distribution agreement with JTI USA designed to grow market for PrimeTime Little Cigars
• SinglePoint debuts, takes orders for Little Cigars at preeminent marijuana business conference
• Global cigar market is currently $10 billion and forecasted to grow at a CAGR of 4.23% from 2019 to 2024

SinglePoint Inc. (OTCQB: SING), a company that specializes in acquisitions of small to mid-sized companies with an emphasis in new technologies, announced that it has inked a new distribution agreement with JTI USA that could significantly grow the footprint of PrimeTime™ Little Cigars throughout North America (http://ibn.fm/Xv3cF).

“I’m excited and honored to be working with JTI to distribute PrimeTime Little Cigars,” SinglePoint CEO Greg Lambrecht stated in a news release. “The opportunity to work with a global leader in this category is exciting, and we are ready to expand Primetime’s U.S. market share with our unique experience in alternative markets. Having placed premium cigars in over 30,000 accounts, we expect this opportunity to be one of our major revenue sources in coming years, and to distribute additional JTI products as we grow this category.”

Shortly after announcing the distribution agreement, SinglePoint took its first step in its new distribution role, debuting the PrimeTime Little Cigars at the 2019 MJBIZCON show, held last week in Las Vegas. At the show, SING showcased PrimeTime Little Cigars and took its first orders for the product. SING expects the exposure gained and orders taken at the show will lead to additional distribution and alternative-market possibilities.

“We are excited to be working with SinglePoint,” added Renee Duszynski, director of sales for JTI. “SinglePoint CEO Mr. Lambrecht’s prior experience in distribution of premium cigars, we believe, will lead to continued growth of JTI USA products and the PrimeTime brand.”

Part of the JT Group of companies, JTI USA is a multibillion-dollar organization with international presence in 130 countries. As a distributor for JTI, SinglePoint will play an important part as it supports JTI’s efforts to grow the distribution and sales of PrimeTime Little Cigars. According to Mordor Intelligence, the global cigar market is currently $10 billion and forecasted to grow at a CAGR of 4.23% from 2019 to 2024.

Recognized as the best-flavored little cigars on the market, PrimeTime Little Cigars are available in cherry, grape, vanilla, and peach. This high-quality tobacco product line provides a valuable alternative for cost-conscious adult smokers who are looking for quality products.

Founded in 2011, SinglePoint invests in and acquires brands and companies that will benefit from injection of growth capital and its sales and marketing expertise. The company portfolio currently includes solar renewables, hemp and distribution tobacco products. SinglePoint is working to grow to a multinational brand.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• DehydraTECH™ drug delivery platform achieved a 319% higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation
• The technology can be used on the nicotine market, the pharmaceutical market, and the cannabinoid market
• No other company in the world has a patent for improved delivery of all non-psychoactive cannabinoids
• Partnership with one of the world’s largest tobacco companies with up to $12 million in Lexaria funding for clinical investigations and product development

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched a revolutionary technology that accelerates intestinal absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sweeteners or sugars, and other unhealthy practices. It is applicable to absorption of cannabis and nicotine, among other bioactive substances.

According to company data, DehydraTECH™ can be used successfully in multiple industries, including the nicotine market (estimated at approximately $746 billion), the pharmaceutical market (more than $68 billion), as well as the cannabinoid market (estimated at over $10.5 billion) (http://ibn.fm/NpNF4).

DehydraTECH™ is patented for all non-psychoactive cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive cannabinoids. The platform reduces the time of onset of THC by four times on average (http://ibn.fm/NzcIR).

Lexaria is the only company in the world that holds patents for oral delivery of all cannabinoids and nicotine. The company has been awarded 16 patents in the United States and Australia and holds 60 globally pending patents. Recently, Lexaria obtained two patents for treating certain conditions including, but not limited to heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia, and others. The platform has potential applications to treat the common form of dementia as well as other nervous system diseases.

The company has developed its technology based on recognition of the fact that inhalation of drugs into the lungs can be dangerous. Edible ingestion enables much healthier and safer absorption. The platform has also been proven to deliver up to 10 times more of active ingredients than traditional edibles. DehydraTECH™ is the first platform that makes it possible to avail many of the benefits of inhalation while greatly reducing the risks.

Medical researchers have struggled to find ways to penetrate the blood brain barrier effectively to transport beneficial drugs for many years. This barrier exists to block toxic or otherwise dangerous substances from entering the brain and is formed by layers of microvascular endothelial cells inside blood vessels. Lexaria’s DehydraTECH™ drug delivery platform brings beneficial drugs to the brain faster.

In June 2019, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH™ technology. This series built on the company’s original, independent, third-party laboratory in vitro lab experiments began in 2015, which showed utilization of the DehydraTECH™ drug delivery platform increased the absorption levels of cannabidiol (CBD) in human intestinal cells by an impressive 499%. The results of the studies showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH™ technology in comparison with generic industry MCT coconut-oil formulations. Moreover, the animal studies using the enhanced formulation showed an 811% increase of CBD delivery into the blood in comparison with generic MCT coconut-oil formulations.

Additionally, Lexaria recently partnered with one of the world’s largest tobacco companies, which is providing up to $12 million to fund 100% of Lexaria’s portion of the obligations for clinical investigations and development of oral forms of nicotine delivery using the DehydraTECH™ drug delivery platform (http://ibn.fm/JZBKX).

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Plus Products boasts best-selling cannabis product in California in 2019
• Company recently announced transition to HERBL Distribution Solutions as main California distribution partner
• PLUS is growing brand, focusing on both current and new market opportunities

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), a hemp and cannabis food company using nature to bring balance to consumers’ lives, is on a mission to make cannabis safe and approachable. PLUS(TM) is working to build the world’ strongest cannabis brand. Headquartered in San Mateo, California, the company focuses on producing edibles using extracts to ensure compliant, dosable and appetizing products that provide a consistent cannabis experience.

PLUS’s products are ranked as one of the top edibles brands in the state of California, which is the largest legal cannabis market in the United States. The company has the state’s best-selling cannabis product, as well as the best-selling gummies brand in California. At present, PLUS products are available in 360 licensed retailers in the state, and PLUS has sold more than 2.5 million branded units since January 1, 2018 (http://ibn.fm/wtvy4).

Recently, Plus Products announced its transition to HERBL Distribution Solutions as its chief California distribution partner, along with the termination of its distribution relationship with Calyx Brands Inc. HERBL is a leader in the California marketplace with active distribution to more than 600 licensed retailers across the state. PLUS’ internal sales team is working directly with HERBL’s team to facilitate a speedy and efficient transition for PLUS’ current retail partners and to open new accounts moving ahead (http://ibn.fm/wn37D).

“After an extensive review of the major California cannabis distributors, we determined that HERBL was best positioned to scale with PLUS and reliably deliver product to retailers at the lowest cost,” PLUS co-founder and CEO Jake Heimark stated in a news release. “Their substantial market reach and world-class management team give us confidence that they will help PLUS further solidify our position as the largest cannabis-infused gummies brand in California.”

In California, PLUS has established its iconic product: PLUS Gummies (cannabis infused). Its Plus Uplift Sour Watermelon was the best-selling cannabis product in California in 2019.

Of note to investors is that Plus Products is centered on quality growth in California and beyond. Its emphasis is on thoughtfully building a brand in a strategic, deliberate approach. The company is growing its brand through new markets, new products and new consumers.

Plus Products continues to be driven by its dedication to premier dosable products. For investors, PLUS is marketing creatively including product launch partnerships with American Superstar John Legend and direct-to-consumer sleep pioneer Casper. PLUS recently entered the National Hemp CBD market expected to exceed $20 billion by 2022.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• SHRG posts record Q2 revenues, cumulative sales of $169 million since launching proprietary line of products.
• CEO says record sales demonstrate that SHRG sales, support strategies are on the right path.
• Company officials believe SHRG will be able to fund working capital needs for the next year with existing cash and cash equivalents with cash provided through operations and secured and unsecured debt, including through issuance of convertible notes and short-term borrowings under financing arrangements and occasional capital transactions

In its most recent SEC filing, Sharing Services Global Corporation (OTCQB: SHRG), a diversified holdings company in the direct-selling industry, posted record Q2 revenues and cumulative sales of $169 million since the company launched its own proprietary line of products (http://ibn.fm/fqmLo). Specifically, the company reported record-breaking revenues of $38.9 million for its fiscal quarter ended October 31, 2019, more than double the $18 million revenues reported in the comparable quarter of fiscal 2019.

“Product sales for our incredible health and wellness products of Elevacity Global continue to be strong, consistently increasing each quarter,” SHRG CEO John “JT” Thatch stated in a news release. “Our Q2 revenues demonstrate that our sales and support strategies are on the right path as we continue to grow in the direct selling marketplace. We attribute our success to our independent distributors, which we refer to as Elepreneurs, and our incredible team at the corporate offices.”

SHRG’s financial numbers were reported in its most recent quarterly report filed with the Securities and Exchange Commission (http://ibn.fm/ZAbhv), which noted that “the accompanying consolidated financial statements have been prepared on a going concern basis, which assumes the company will be able to realize its assets and settle its liabilities in the ordinary course of its business for the foreseeable future.”

Noting that the company is an emerging growth company and, prior to its fiscal quarter ended January 31, 2018, it had virtually no sales, the filing then reported that SHRG’s “quarterly net sales have increased, and gross margin has expanded each quarter since the December 2017 launch of its Elevate health and wellness product line. For the full fiscal year ended April 30, 2019, cash provided by operations was $6.0 million on annual sales of $85.9 million. In addition, for the six months ended October 31, 2019, cash provided by operations was $12.1 million on sales of $74.3 million, while operating earnings were $3.9 million. As of October 31, 2019, cash and cash equivalents were $12.8 million.”

In the filing, company officials reported that they believe SHRG will be able to fund working capital needs for the next year with existing cash and cash equivalents, with cash provided through operations and secured and unsecured debt, including through the issuance of convertible notes and short-term borrowings under financing arrangements and capital transactions from time to time. “The company believes there is no longer reasonable doubt as to [its] ability to continue as a going concern in the foreseeable future,” the filing noted.

“SHRG will continue its efforts to expand revenues through its subsidiaries by added support, expansion efforts and by bringing on additional experienced industry talent to help these efforts on a large scale,” Thatch stated in a news release. “The company will continue to evaluate its expansion plans, products and strategies to continue its success as we enter into 2020.”

Sharing Services Global Corporation is a diversified company, with Elepreneurs Holdings and Elevacity Holdings being its primary operating subsidiaries. SHRG markets and distributes health and wellness products that are sold under the Elevate brand through an independent sales force of distributors, or Elepreneurs, using the direct-selling business model. Sharing Service’s current product offerings include its Elevate health and wellness product line, launched in December 2017. The company’s Elevate product line consists of nutraceutical products referred to as D.O.S.E., which refers to the key hormones dopamine, oxytocin, serotonin, and endorphins.

Sharing Services is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling industry. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG